Dupixent COPD denied due to quantity / dose limits by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for dupixent copd are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Applied Quantity Limits to Dupixent for COPD

A quantity-limit denial means UnitedHealthcare's system flagged that the amount or frequency of Dupixent (dupilumab) prescribed exceeds the quantity the plan will cover per fill, per month, or per year. For a self-administered biologic like dupilumab, quantity limits are typically set to align with the FDA-approved dosing regimen. This means the most common reason for this denial is a mismatch between how the prescription was written and what UHC expects — either a prescribing or dispensing discrepancy, or in some cases a plan that applies quantity limits more restrictively than the label.

## Federal Appeal Rights

• ERISA §503 requires full-and-fair internal review with written reasoning for employer-sponsored plans.
• ACA §2719 provides external IRO review rights when the denial has a clinical basis.
• Internal appeal: typically 180 days from the denial notice.
• External review: typically 4 months from final internal denial.
• Expedited review: available when delay would seriously jeopardize your health.

## Step 1: Identify the Mismatch

Before appealing, confirm the following:

1. How was the prescription written? Compare the prescribed quantity and frequency to the FDA-approved prescribing label dosing regimen for the COPD indication. 2. What does UHC's quantity limit allow? Request UHC's current quantity-limit schedule or the specific limit applied to your claim. 3. Is this a dispensing or coding error? Pharmacies sometimes dispense in package configurations that trigger a quantity-limit flag even when the clinical intent matches the label. Your prescriber's office or pharmacist may be able to resolve this administratively.

## What to Gather for a Clinical Quantity-Limit Appeal

1. FDA-approved prescribing label — document the approved dosing frequency for the COPD indication. If the prescribed regimen matches the label exactly, state that clearly in the appeal. 2. Prescriber clinical justification — if a non-standard quantity is medically necessary (e.g., a loading dose or adjusted schedule documented in chart), the prescriber must provide a written explanation tied to your specific clinical circumstances. 3. Diagnosis and severity documentation — chart notes confirming COPD, type-2 inflammatory phenotype, exacerbation burden, and current disease status. 4. UHC's quantity-limit policy — obtain the current policy and compare it to the FDA label. If UHC's limit is more restrictive than the label without clinical justification, note the discrepancy in your appeal. 5. Pharmacy dispensing records — confirm the quantity dispensed and the NDC code used, as these affect how the claim is adjudicated.

## Criteria-Mapping Structure

| Quantity-Limit Issue | Resolution / Evidence | |---|---| | Prescribed quantity exceeds UHC limit | Compare to FDA label; if label-concordant, cite label and request exception | | Non-standard quantity prescribed | Prescriber letter explaining clinical rationale and chart basis | | Dispensing configuration mismatch | Pharmacy and prescriber coordinate on correct NDC/quantity submission |

If the prescribed quantity aligns with the FDA label and UHC's limit is more restrictive, escalate to IRO external review — IRO reviewers assess whether the plan's limit is clinically supportable. IRO decisions are binding on UHC.